WO2019083256A3 - 변형된 egf 단백질, 이의 생산 방법 및 용도 - Google Patents

변형된 egf 단백질, 이의 생산 방법 및 용도 Download PDF

Info

Publication number
WO2019083256A3
WO2019083256A3 PCT/KR2018/012569 KR2018012569W WO2019083256A3 WO 2019083256 A3 WO2019083256 A3 WO 2019083256A3 KR 2018012569 W KR2018012569 W KR 2018012569W WO 2019083256 A3 WO2019083256 A3 WO 2019083256A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
egf protein
modified egf
protein
modified
Prior art date
Application number
PCT/KR2018/012569
Other languages
English (en)
French (fr)
Other versions
WO2019083256A2 (ko
Inventor
양정윤
남은주
Original Assignee
주식회사 프로젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180125012A external-priority patent/KR102190790B1/ko
Application filed by 주식회사 프로젠 filed Critical 주식회사 프로젠
Priority to CN201880083629.3A priority Critical patent/CN111836826B/zh
Priority to JP2020542519A priority patent/JP6963336B2/ja
Priority to US16/757,823 priority patent/US11339197B2/en
Priority to EP18871487.7A priority patent/EP3702365A4/en
Publication of WO2019083256A2 publication Critical patent/WO2019083256A2/ko
Publication of WO2019083256A3 publication Critical patent/WO2019083256A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 변형된 EGF 단백질, 이의 생산 방법 및 용도에 관한 것이다. 본 발명에 따른 변형된 EGF 단백질은 세포막과 결합하여 EGF를 효율적으로 세포 내로 전달함으로써 세포 투과율 및 반감기를 증가시킬 수 있다. 또한, 상기 변형된 EGF 단백질은 가혹한 조건 속에서도 EGF가 온전한 형태로 유지되어 장기적인 안정성이 향상됨으로써 단백질 변성으로 인해 보존 기간이 짧고, 보관 및 유통이 까다로운 화장료 조성물 및 약학 조성물에 매우 효과적으로 적용될 수 있다. 또한, 본 발명에 따른 변형된 EGF 단백질 생산 방법은, 활성을 갖고 있는 형태의 변형된 EGF 단백질로 생산 가능하며, 최적의 배양 온도 및 PH 조건 확립을 통해 생산성이 우수하여 상업적으로 활용 가능하다. 본 발명은 일 실시예에서, 2.3g/L 이상의 생산성 및 75% 이상의 정제 수율을 나타내는 변형된 EGF 단백질을 생산하였으며, 이를 통해 본 발명에 따른 변형된 EGF 단백질 생산 방법의 우수성을 입증하였다. 따라서, 본 발명의 변형된 EGF 단백질은 기존의 EGF 단백질 대비 세포 투과성, 생체 내 지속성 및 안정성이 우수한 바, 화장료 조성물 또는 약학 조성물로 활용될 수 있다.
PCT/KR2018/012569 2017-10-23 2018-10-23 변형된 egf 단백질, 이의 생산 방법 및 용도 WO2019083256A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880083629.3A CN111836826B (zh) 2017-10-23 2018-10-23 修饰的egf蛋白，其制备方法及其用途
JP2020542519A JP6963336B2 (ja) 2017-10-23 2018-10-23 改変ｅｇｆタンパク質、その製造方法及びその使用
US16/757,823 US11339197B2 (en) 2017-10-23 2018-10-23 Modified EGF protein, production method therefor, and use thereof
EP18871487.7A EP3702365A4 (en) 2017-10-23 2018-10-23 MODIFIED EGF PROTEIN, ITS PRODUCTION PROCESS AND ITS USE

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20170137132 2017-10-23
KR20170137140 2017-10-23
KR10-2017-0137140 2017-10-23
KR10-2017-0137132 2017-10-23
KR1020180125012A KR102190790B1 (ko) 2018-10-19 2018-10-19 변형된 egf 단백질의 생산 방법
KR10-2018-0125012 2018-10-19

Publications (2)

Publication Number Publication Date
WO2019083256A2 WO2019083256A2 (ko) 2019-05-02
WO2019083256A3 true WO2019083256A3 (ko) 2019-06-13

Family

ID=66246628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012569 WO2019083256A2 (ko) 2017-10-23 2018-10-23 변형된 egf 단백질, 이의 생산 방법 및 용도

Country Status (5)

Country Link
US (1) US11339197B2 (ko)
EP (1) EP3702365A4 (ko)
JP (1) JP6963336B2 (ko)
CN (1) CN111836826B (ko)
WO (1) WO2019083256A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116239667B (zh) * 2022-07-21 2024-05-10 西南大学 具有促细胞增殖活性的ehEGF重组蛋白及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211579A1 (en) * 2002-03-27 2003-11-13 van Ness Kirk P. Methods for increasing polypeptide production
US20030228612A1 (en) * 2002-04-30 2003-12-11 Kenward Kimberly D. Production of recombinant epidermal growth factor in plants
US7517528B2 (en) * 2002-03-12 2009-04-14 Bio-Click Technologies, Ltd. Method and composition for treating skin wounds with epidermal growth factor
WO2014097733A1 (ja) * 2012-12-21 2014-06-26 株式会社ＵｎｉＢｉｏ ヒト上皮細胞増殖因子の製造方法
KR20160113880A (ko) * 2015-03-23 2016-10-04 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
KR100583350B1 (ko) 2004-11-03 2006-06-05 (주)넥스젠 Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
KR101519118B1 (ko) 2013-07-23 2015-05-12 (주)피앤피바이오팜 고안정성 상피세포 성장인자 변이체
US9321821B2 (en) 2013-11-14 2016-04-26 Lg Household & Health Care Ltd. Cosmetic composition for improving skin conditions comprising fusion protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517528B2 (en) * 2002-03-12 2009-04-14 Bio-Click Technologies, Ltd. Method and composition for treating skin wounds with epidermal growth factor
US20030211579A1 (en) * 2002-03-27 2003-11-13 van Ness Kirk P. Methods for increasing polypeptide production
US20030228612A1 (en) * 2002-04-30 2003-12-11 Kenward Kimberly D. Production of recombinant epidermal growth factor in plants
WO2014097733A1 (ja) * 2012-12-21 2014-06-26 株式会社ＵｎｉＢｉｏ ヒト上皮細胞増殖因子の製造方法
KR20160113880A (ko) * 2015-03-23 2016-10-04 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법

Also Published As

Publication number Publication date
CN111836826A (zh) 2020-10-27
EP3702365A2 (en) 2020-09-02
US11339197B2 (en) 2022-05-24
EP3702365A4 (en) 2021-11-10
CN111836826B (zh) 2024-01-02
US20210188931A1 (en) 2021-06-24
JP2021500069A (ja) 2021-01-07
WO2019083256A2 (ko) 2019-05-02
JP6963336B2 (ja) 2021-11-05

Similar Documents

Publication Publication Date Title
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
EA202190326A3 (ru) Не содержащая сыворотки среда для культивирования клеток
AU2015208482A1 (en) Fusion protein inhibiting angiogenesis or growth and use thereof
IN2012DN00801A (ko)
MY197672A (en) Room temperature stable lyophilized protein
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
EA201401211A1 (ru) Улучшенные варианты фермента химозина
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
EA202091349A1 (ru) Способы культивирования клеток
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
PH12017502323A1 (en) Novel xylanase
RU2017142878A (ru) Микроорганизм рода Escherichia, обладающий продуктивностью по L-триптофану, и способ получения L-триптофана с его использованием
WO2019083256A3 (ko) 변형된 egf 단백질, 이의 생산 방법 및 용도
SA518400042B1 (ar) مترافق من فيناستيريد مع ببتيد
MX2018015388A (es) Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas.
WO2018183848A8 (en) Media for microorganism culture and related compositions and methods
PH12021551234A1 (en) Botulinum toxin-stabilizing liquid composition
BR112016024493A2 (pt) amilase, ácido nucleico, conjunto de expressão, célula hospedeira recombinante, composição de enzima e método de tratamento de substâncias
MY193527A (en) Conjugate of minoxidil and peptide
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
WO2023114936A3 (en) Subtilisin variants and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18871487

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020542519

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018871487

Country of ref document: EP

Effective date: 20200525